J.W. Cole Advisors Inc. Has $814,000 Stock Holdings in Edwards Lifesciences Corporation (NYSE:EW)

J.W. Cole Advisors Inc. increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 220.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,224 shares of the medical research company's stock after purchasing an additional 7,719 shares during the quarter. J.W. Cole Advisors Inc.'s holdings in Edwards Lifesciences were worth $814,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Prosperity Consulting Group LLC lifted its stake in Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after purchasing an additional 134 shares during the last quarter. Arlington Trust Co LLC grew its holdings in Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after acquiring an additional 135 shares during the period. Valeo Financial Advisors LLC grew its holdings in Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after acquiring an additional 142 shares during the period. Versant Capital Management Inc grew its holdings in Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after purchasing an additional 145 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 5,980 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $74.91, for a total value of $447,961.80. Following the transaction, the chief executive officer owned 58,284 shares in the company, valued at $4,366,054.44. The trade was a 9.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the transaction, the vice president owned 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,848 shares of company stock valued at $2,314,488. Corporate insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EW. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Truist Financial increased their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday. Deutsche Bank Aktiengesellschaft raised their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday. Finally, Mizuho raised their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $84.29.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded up $4.12 during mid-day trading on Friday, reaching $79.92. The company had a trading volume of 15,656,685 shares, compared to its average volume of 3,810,979. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a market cap of $46.88 billion, a PE ratio of 11.50, a P/E/G ratio of 3.81 and a beta of 1.11. The company has a 50-day moving average price of $76.58 and a two-hundred day moving average price of $73.56. Edwards Lifesciences Corporation has a 1-year low of $59.41 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.70 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.